Cenderitide

Summary

Cenderitide (CD-NP) is a chimeric natriuretic peptide developed by the Mayo Clinic, designed to treat acute and chronic heart failure. It combines sequences of CNP and DNP to provide balanced natriuretic, diuretic, and renal-protective effects with potentially reduced hypotensive side effects compared to existing natriuretic peptides like nesiritide.

Mechanism of Action

Chimeric natriuretic peptide that activates both natriuretic peptide receptor-A (NPR-A) and natriuretic peptide receptor-C (NPR-C), promoting natriuresis, diuresis, and vasodilation while suppressing aldosterone and renin. Combines C-type natriuretic peptide (CNP) and Dendroaspis natriuretic peptide (DNP) sequences to achieve dual receptor engagement.

Routes of Administration

Goals & Uses

• Chronic heart failure treatmentCardiovascularLow
• Natriuresis and diuresis promotionRenal/CardiovascularModerate
• Renal protection in heart failureRenalLow
• Acute decompensated heart failure managementCardiovascularModerate
• Renin-angiotensin-aldosterone system suppressionNeurohormonalModerate

Contraindications

• Cardiogenic shockCardiovascularHigh
• Hypersensitivity to natriuretic peptidesImmunologicalHigh
• Severe renal failure (anuria)RenalModerate
• Severe hypotensionCardiovascularHigh

Adverse Effects

• Increased serum creatinineRenalUncommon
• Injection site reactionsLocalUncommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• HypotensionCardiovascularCommonLow blood pressure
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• Antihypertensive agentsModerate
• ACE inhibitors / ARBsModerate
• DiureticsModerateMay worsen dehydration or electrolyte imbalance

Population Constraints

• Pediatric patientsAgeRelative
• Elderly patients (≥75 years)AgeRelative
• Pregnant womenReproductiveRelative
• Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; limited European clinical trial data available.
• United StatesInvestigationalInvestigated under IND; not FDA approved. Phase I and II trials completed; no NDA filed as of last available data.
• United KingdomUnknownNo MHRA approval identified; research status assumed.

Not approved by any regulatory agency. Investigated in Phase I and Phase II clinical trials primarily for acute decompensated heart failure and chronic heart failure. No FDA or EMA approval as of current knowledge.

Evidence & Sources

No sources recorded yet.